Remove 2019 Remove Cannabis Remove Clinical Trials Remove Safety
article thumbnail

IGC Completes Cohort 2 of its Phase 1 THC-Based Clinical Trial on Alzheimer’s Patients

Cannabis Law Report

IGC”) (NYSE American: IGC) announces today that it has completed Cohort 2 of its Phase 1 clinical trial on IGC’s tetrahydrocannabinol (“THC”)-based investigational new drug, IGC-AD1, intended to alleviate the symptoms of individuals suffering from Alzheimer’s disease. This Phase 1 trial is currently testing IGC-AD1 for safety.

article thumbnail

South African Research Team Says Cannabis is ‘Very Promising’ as an Opioid Replacement

Veriheal

Clinical trials into cannabis’ potential as an opioid replacement are well underway in South Africa. ” Dr. Gallow prides himself on his work as a South African cannabis advocate and leader in the international medical cannabis research field. About the Opioid Epidemic. The survey results showed that 9.7

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Press Release: Beckley Psytech Announces Partnership With Ksana Health, Building on Digital Strategy to Deliver Optimised Patient Outcomes

Cannabis Law Report

Partnership will focus on the collection and analysis of digital biomarkers to identify signs of response and relapse in upcoming Phase 2 clinical trials. However, we need rigorous clinical trials to ensure that this promise is realised. June 14, 2022 02:00 AM Eastern Daylight Time. Ksana Health – www.ksanahealth.com.

article thumbnail

GW Pharmaceuticals Pre-Announces Preliminary Unaudited Fourth Quarter and Full-Year 2019 Net Product Sales

Cannabis Law Report

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. 14th at 11:00 a.m. PT (2:00 p.m.

article thumbnail

Press Release: This is the FIRST Public Psychedelics Company to Notch a Patent for Extracting Natural Psilocybin

Cannabis Law Report

Although the overarching market is still relatively new, much like the cannabis boom a few years ago the psychedelics space is growing at an unprecedented rate. billion in 2019. Over the next several years, the psychedelics industry is expected to grow at a compound annual growth rate of 16.3 per cent to reach US$6.86

article thumbnail

Cannabis Helps, Say Over Half of Parkinson’s Patients Who Use It

The Cannigma

This article was originally published on Analytical Cannabis and appears here with permission. . In a new survey of German patients with Parkinson’s disease, 8% of patients reported using cannabis products. Of these consumers, over half said the drug had a beneficial clinical effect on their condition.

article thumbnail

‘Too costly, not enough evidence it works’, says UK in blow to cannabis campaigners

Cannabis Law Report

PUBLISHER: CANNABIS LAW REPORT. Cannabis treatments are too expensive and do not come with enough test evidence to be effective, UK authorities have said. It also said the children’s experiences on medicinal cannabis in the should be taken into account as evidence of how well the drug works. AUTHOR: Mark Taylor.